GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004211010 | Prostate | BPH | T cell activation | 111/3107 | 487/18723 | 2.11e-04 | 1.72e-03 | 111 |
GO:00026839 | Prostate | BPH | negative regulation of immune system process | 100/3107 | 434/18723 | 2.83e-04 | 2.20e-03 | 100 |
GO:00508563 | Prostate | BPH | regulation of T cell receptor signaling pathway | 16/3107 | 41/18723 | 5.01e-04 | 3.57e-03 | 16 |
GO:000715910 | Prostate | BPH | leukocyte cell-cell adhesion | 86/3107 | 371/18723 | 5.95e-04 | 4.11e-03 | 86 |
GO:00508526 | Prostate | BPH | T cell receptor signaling pathway | 35/3107 | 123/18723 | 6.68e-04 | 4.48e-03 | 35 |
GO:190303710 | Prostate | BPH | regulation of leukocyte cell-cell adhesion | 78/3107 | 336/18723 | 9.95e-04 | 6.25e-03 | 78 |
GO:00480085 | Prostate | BPH | platelet-derived growth factor receptor signaling pathway | 19/3107 | 56/18723 | 1.19e-03 | 7.31e-03 | 19 |
GO:005086310 | Prostate | BPH | regulation of T cell activation | 76/3107 | 329/18723 | 1.32e-03 | 7.95e-03 | 76 |
GO:00466343 | Prostate | BPH | regulation of alpha-beta T cell activation | 29/3107 | 104/18723 | 2.58e-03 | 1.38e-02 | 29 |
GO:00466313 | Prostate | BPH | alpha-beta T cell activation | 40/3107 | 156/18723 | 2.58e-03 | 1.38e-02 | 40 |
GO:00508542 | Prostate | BPH | regulation of antigen receptor-mediated signaling pathway | 19/3107 | 63/18723 | 5.36e-03 | 2.49e-02 | 19 |
GO:00508604 | Prostate | BPH | negative regulation of T cell receptor signaling pathway | 9/3107 | 22/18723 | 5.92e-03 | 2.73e-02 | 9 |
GO:00224085 | Prostate | BPH | negative regulation of cell-cell adhesion | 46/3107 | 196/18723 | 7.95e-03 | 3.47e-02 | 46 |
GO:00421299 | Prostate | BPH | regulation of T cell proliferation | 41/3107 | 171/18723 | 8.09e-03 | 3.52e-02 | 41 |
GO:00466402 | Prostate | BPH | regulation of alpha-beta T cell proliferation | 12/3107 | 35/18723 | 8.36e-03 | 3.61e-02 | 12 |
GO:00706639 | Prostate | BPH | regulation of leukocyte proliferation | 55/3107 | 245/18723 | 1.02e-02 | 4.29e-02 | 55 |
GO:004209810 | Prostate | BPH | T cell proliferation | 46/3107 | 199/18723 | 1.05e-02 | 4.39e-02 | 46 |
GO:007259417 | Prostate | Tumor | establishment of protein localization to organelle | 151/3246 | 422/18723 | 3.19e-20 | 2.83e-17 | 151 |
GO:004217619 | Prostate | Tumor | regulation of protein catabolic process | 142/3246 | 391/18723 | 9.32e-20 | 5.79e-17 | 142 |
GO:000989619 | Prostate | Tumor | positive regulation of catabolic process | 155/3246 | 492/18723 | 5.62e-15 | 8.52e-13 | 155 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0510039 | Esophagus | HGIN | Bacterial invasion of epithelial cells | 30/1383 | 77/8465 | 1.49e-06 | 2.31e-05 | 1.84e-05 | 30 |
hsa0520528 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa05100114 | Esophagus | HGIN | Bacterial invasion of epithelial cells | 30/1383 | 77/8465 | 1.49e-06 | 2.31e-05 | 1.84e-05 | 30 |
hsa05205112 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0522020 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05100211 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0401218 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05220110 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05100310 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CBL | SNV | Missense_Mutation | rs759585425 | c.1028N>A | p.Arg343Gln | p.R343Q | P22681 | protein_coding | tolerated(0.07) | possibly_damaging(0.68) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.397N>C | p.Phe133Leu | p.F133L | P22681 | protein_coding | tolerated(0.22) | probably_damaging(1) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.293N>C | p.Ile98Thr | p.I98T | P22681 | protein_coding | deleterious(0.02) | benign(0.422) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
CBL | SNV | Missense_Mutation | novel | c.1501N>C | p.Asp501His | p.D501H | P22681 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CBL | SNV | Missense_Mutation | | c.1619N>C | p.Arg540Pro | p.R540P | P22681 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.997) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CBL | deletion | Frame_Shift_Del | novel | c.2287delN | p.Gly763ValfsTer103 | p.G763Vfs*103 | P22681 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CBL | SNV | Missense_Mutation | novel | c.570N>C | p.Trp190Cys | p.W190C | P22681 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
CBL | SNV | Missense_Mutation | | c.1366N>A | p.Asp456Asn | p.D456N | P22681 | protein_coding | deleterious(0) | benign(0.439) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.416N>T | p.Arg139Ile | p.R139I | P22681 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.617N>A | p.Arg206Gln | p.R206Q | P22681 | protein_coding | tolerated(0.09) | probably_damaging(0.978) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Fasudil | FASUDIL | 26177294 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | ANTISENSE OLIGONUCLEOTIDES | | 8849724 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Gemcitabine | GEMCITABINE | 25348515 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | DASATINIB | DASATINIB | 23696637 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | SU11274 | | 28835699 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | N/A | | 26230957,23690417,19901108 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Quizartinib | QUIZARTINIB | 22990016 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | IL-2 | ALDESLEUKIN | 9461587 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Erlotinib | ERLOTINIB | 25348515 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | FLT3-LIGAND | | 17446348 |